| Identification | Back Directory | [Name]
4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one | [CAS]
883065-90-5 | [Synonyms]
BI 78D3
CS-1070
BI-78D3 >=98% (HPLC)
JNK Inhibitor X, BI-78D3
JNK Inhibitor X, BI-78D3 - CAS 883065-90-5 - Calbiochem
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-2-thiazolyl)thio]-1H-1,2,4-triazol-5-one
4-(2,3-Dihydrobenzol[b][1,4]dioxin-6-yl)-5-(5-nitrothiazol-2-ylthio)-4H-1,2,4-triazol-3-ol
4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-3-((5-nitro-thiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-
4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-3-((5-nitro-thiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-one
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1H-1,2,4-triazol-5-one
4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one
3H-1,2,4-Triazol-3-one, 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]- | [Molecular Formula]
C13H9N5O5S2 | [MDL Number]
MFCD01313575 | [MOL File]
883065-90-5.mol | [Molecular Weight]
379.37 |
| Chemical Properties | Back Directory | [density ]
1.92±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO: >10mg/mL | [form ]
powder | [pka]
2.76±0.20(Predicted) | [color ]
tan | [InChI]
1S/C13H9N5O5S2/c19-11-15-16-12(25-13-14-6-10(24-13)18(20)21)17(11)7-1-2-8-9(5-7)23-4-3-22-8/h1-2,5-6H,3-4H2,(H,15,19) | [InChIKey]
QFRLDZGQEZCCJZ-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Uses]
BI-78D3 is an inhibitor of JNK mediated signaling. Molecular docking studies on JNK inhibitors at allosteric JNK-JIP interaction site. JNK inhibition by BI-78D3 covalent binding to JNK at Cys163 or displacement of 2-mercapto-5-nitrothiazole, or addition of BI-78D3 oxidation product. A therapeutic target of the vascular JNK pathway which improves retinal endothelial vasodilator function during early diabetes. | [Definition]
ChEBI: 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-2-thiazolyl)thio]-1H-1,2,4-triazol-5-one is an aryl sulfide. | [Biological Activity]
bi-78d3 is a substrate competitive inhibitor of jnk inhibitor [2].jnk is a member of the mapk family. jnk is a stress-activated protein kinase that modulates pathways implicated in a variety of disease states. non-motoric jnk functions may differ between cell types and organs. the jnk is involved in a1-adrenoceptor-mediated contraction of prostate smooth muscle. for non-malignant, epithelial human prostate cells, jnk activation not only has the function of pro-apoptotic and antiproliferative but also related with jnk-dependent survival.[1]bi-78d3 is competitive with atf2 for binding to jnk1 with an apparent ki value of 200 nm. in addition, it has been reported that bi-78d3 does not inhibit the phosphorylation of a short peptide substrate lacking a d-domain. this confirms that bi-78d3 is substrate competitive.[2]bi-78d3 inhibits both noradrenaline- and phenylephrine-induced contractions. then it prevents α1-adrenoceptor-mediated contraction of prostate tissue. as an effective jnk inhibitor, bi-78d3 has the ability of abrogating cona-induced liver damage and restoring insulin sensitivity. [1,2] | [in vivo]
The link between ConA-induced liver failure, TNF receptor signaling, and JNK function has been established by studies employing JNK1-/- and JNK2-/- mice. For this analysis, insulin insensitive mice are injected only once with 25 mg/kg BI-78D3, 30 min before insulin injection. The effect of insulin on blood glucose levels is then measured. BI-78D3 results in a statistically significant reduction in blood glucose levels as compared with the vehicle control. Thus, the ability of BI-78D3 to abrogate ConA-induced liver damage and restore insulin sensitivity is consistent with its proposed function as an effective JNK inhibitor. Liquid chromatography/mass spectrometry bio-availability analysis demonstrates that BI-78D3 has favorable microsome and plasma stability (T1/2=54 min)[1]. | [IC 50]
JNK: 280 nM (IC50) | [storage]
Store at +4°C | [References]
[1] strittmatter f1, walther s, gratzke c, etal. , inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-jun n-terminal kinase, sp600125 and bi-78d3. br j pharmacol. 2012 jul;166(6):1926-35.
[2] stebbins jl, de sk, machleidt t,etal. , identification of a new jnk inhibitor targeting the jnk-jip interaction site. proc natl acad sci u s a. 2008 oct 28;105(43):16809-13. |
|
|